Latest Developments in Global Avian Influenza Drug Market
- In December 2022, Hester Biosciences Ltd., an India-based animal and poultry vaccine manufacturing company, acquired the technology from the Indian Council of Agricultural Research and the National Institute of High-Security Animal Diseases (ICAR-NIHSAD) for an undisclosed amount. With this technology acquisition, the aim of Hester Biosciences acquiring the technology to develop an inactivated H9N2 avian influenza vaccine for poultry is to provide a solution to the significant economic losses faced by Indian poultry farmers due to periodic outbreaks of the disease. The Indian Council of Agricultural Research, National Institute of High Security Animal Diseases (ICAR-NIHSAD), is an India-based research institute that offers technology for aviation flu vaccines and diagnostic tests for avian influenza.
- In February 2024, Zoetis Inc. announced the launch of a new recombinant avian influenza vaccine targeting emerging H5N1 variants. In June 2024, Ceva Santé Animale introduced its Vectormune AI H9 vaccine across Asia-Pacific markets to help manage rising H9N2 outbreaks. Both launches aim to enhance protection against evolving strains and improve poultry health outcomes.
